These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32885992)

  • 41. Hypercalcemia of malignancy in the palliative care patient: a treatment strategy.
    Kovacs CS; MacDonald SM; Chik CL; Bruera E
    J Pain Symptom Manage; 1995 Apr; 10(3):224-32. PubMed ID: 7543127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypercalcemia of malignancy.
    Body JJ
    Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH; Alzaid AA; Gardner MD; Boyle IT
    Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia.
    Singer FR
    Semin Oncol; 1990 Apr; 17(2 Suppl 5):34-9. PubMed ID: 2110387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
    Nussbaum SR; Warrell RP; Rude R; Glusman J; Bilezikian JP; Stewart AF; Stepanavage M; Sacco JF; Averbuch SD; Gertz BJ
    J Clin Oncol; 1993 Aug; 11(8):1618-23. PubMed ID: 8336198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
    Thürlimann B; Waldburger R; Senn HJ; Thiébaud D
    Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy.
    Adami S; Bolzicco GP; Rizzo A; Salvagno G; Bertoldo F; Rossini M; Suppi R; Lo Cascio V
    Bone Miner; 1987 Aug; 2(5):395-404. PubMed ID: 2975514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
    Blind E; Raue F; Meinel T; Wüster C; Ziegler R
    Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
    Lortholary A
    Rev Med Interne; 2001 Jul; 22(7):648-52. PubMed ID: 11508158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
    Harinck HI; Bijvoet OL; Plantingh AS; Body JJ; Elte JW; Sleeboom HP; Wildiers J; Neijt JP
    Am J Med; 1987 Jun; 82(6):1133-42. PubMed ID: 3300303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
    Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
    J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zoledronic acid: a new parenteral bisphosphonate.
    Li EC; Davis LE
    Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypercalcemia of Malignancy and Acute Pancreatitis.
    Imam Z; Hanna A; Jomaa D; Khasawneh M; Abonofal A; Murad MH
    Pancreas; 2021 Feb; 50(2):206-213. PubMed ID: 33565797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Electrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin, and furosemide administration for hypercalcemia of malignancy.
    Kadar E; Rush JE; Wetmore L; Chan DL
    J Am Anim Hosp Assoc; 2004; 40(1):75-81. PubMed ID: 14736909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
    Young G; Shende A
    Med Pediatr Oncol; 1998 Feb; 30(2):117-21. PubMed ID: 9403021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
    Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
    J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
    Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.